Search

Your search keyword '"HAZAR, VOLKAN"' showing total 344 results
Start Over Author "HAZAR, VOLKAN"
344 results on '"HAZAR, VOLKAN"'

3. Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

Author

Yesilipek, M. Akif, Uygun, Vedat, Kupesiz, Alphan, Karasu, Gulsun, Ozturk, Gulyuz, Ertem, Mehmet, Şaşmaz, İlgen, Daloğlu, Hayriye, Güler, Elif, Hazar, Volkan, Fisgin, Tunç, Sezgin, Gülay, Kansoy, Savaş, Kuşkonmaz, Barış, Akıncı, Burcu, Özbek, Namık, İnce, Elif Ünal, Öztürkmen, Seda, Küpesiz, Funda Tayfun, Yalçın, Koray, Anak, Sema, Bozkurt, Ceyhun, Karakükçü, Musa, Küpeli, Serhan, Albayrak, Davut, Öniz, Haldun, Aksoylar, Serap, Okur, Fatma Visal, Albayrak, Canan, Yenigürbüz, Fatma Demir, Bozkaya, İkbal Ok, İleri, Talia, Gürsel, Orhan, Karagün, Barbaros Şahin, Kintrup, Gülen Tüysüz, Çelen, Suna, Elli, Murat, Aksoy, Basak Adaklı, Yılmaz, Ebru, Tanyeli, Atila, Akyol, Şule Turan, Siviş, Zuhal Önder, Özek, Gülcihan, Uçkan, Duygu, Kartal, İbrahim, Atay, Didem, Akyay, Arzu, Bilir, Özlem Arman, Çakmaklı, Hasan Fatih, Kürekçi, Emin, Malbora, Barış, Akbayram, Sinan, Demir, Hacı Ahmet, Kılıç, Suar Çakı, Güneş, Adalet Meral, Zengin, Emine, Özmen, Salih, and Antmen, Ali Bülent

Published
2022
Full Text
View/download PDF

4. COVID‐19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group

Author

Bozkurt, Ceyhun, primary, Hazar, Volkan, additional, Malbora, Barış, additional, Küpesiz, Alphan, additional, Aygüneş, Utku, additional, Fışgın, Tunç, additional, Karakükçü, Musa, additional, Kuşkonmaz, Barış, additional, Kılıç, Suar Çakı, additional, Bayırlı, Derya, additional, Arman Bilir, Özlem, additional, Yalçın, Koray, additional, Gözmen, Salih, additional, Uygun, Vedat, additional, Elli, Murat, additional, Sarbay, Hakan, additional, Küpesiz, Funda Tayfun, additional, Şaşmaz, Hatice İlgen, additional, Aksoy, Başak Adaklı, additional, Yılmaz, Ebru, additional, Okur, Fatma Visal, additional, Tekkeşin, Funda, additional, Yenigürbüz, Fatma Demir, additional, Özek, Gülcihan, additional, Atay, Abdullah Avni, additional, Bozkaya, İkbal Ok, additional, Çelen, Suna, additional, Öztürkmen, Seda, additional, Güneş, Adalet Meral, additional, Gürsel, Orhan, additional, Güler, Elif, additional, Özcan, Alper, additional, Çetinkaya, Duygu Uçkan, additional, Aydoğdu, Selime, additional, Özbek, Namık Yaşar, additional, Karasu, Gülsün, additional, Sezgin, Gülay, additional, Doğru, Ömer, additional, Albayrak, Davut, additional, Öztürk, Gülyüz, additional, Aksoylar, Serap, additional, Daloğlu, Hayriye, additional, Odaman Al, Işık, additional, Evim, Melike Sezgin, additional, Akbayram, Sinan, additional, Öncül, Yurday, additional, Zengin, Emine, additional, Albayrak, Canan, additional, Timur, Çetin, additional, Kar, Yeter Düzenli, additional, Çakmaklı, Hasan Fatih, additional, Tüfekçi, Özlem, additional, Töret, Ersin, additional, and Antmen, Bülent, additional

Published
2024
Full Text
View/download PDF

6. Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia

Author

Hazar, Volkan, Öztürk, Gülyüz, Yalçın, Koray, Uygun, Vedat, Aksoylar, Serap, Küpesiz, A., Ok Bozkaya, İkbal, Karagün, Barbaros Şahin, Bozkurt, Ceyhun, İleri, Talia, Atay, Didem, Koçak, Ülker, Karasu, Gülsün Tezcan, Yeşilipek, Akif, Gökçe, Müge, Kansoy, Savaş, Kintrup, Gülen Tüysüz, Karakükcü, Musa, Okur, Fatma Visal, Ertem, Mehmet, Kaya, Zühre, Gürsel, Orhan, Yaman, Yöntem, Özbek, Namık, Antmen, Bülent, Tüfekçi, Özlem, Albayrak, Canan, Adaklı Aksoy, Başak, Sezgin, Gülay, Albayrak, Davut, Evim, Melike Sezgin, Zengin, Emine, and Pekpak, Esra

Published
2021
Full Text
View/download PDF

7. COVID-19 disease in children and adolescents following hematopoietic stem cell transplantation: A report from the Turkish Pediatric Bone Marrow Transplantation Study Group

Author

BOZKURT, CEYHUN, primary, Hazar, Volkan, additional, Malbora, Baris, additional, Küpesiz, Alphan, additional, Aygüneş, Utku, additional, Fısgın, Tunc, additional, Karakükçü, Musa, additional, Kuskonmaz, Baris, additional, Kilic, Suar Çakı, additional, Bayırlı, Derya, additional, Bilir, Özlem Arman, additional, Yalcin, Koray, additional, Gözmen, Salih, additional, Uygun, Vedat, additional, Elli, Murat, additional, Sarbay, Hakan, additional, Küpesiz, Funda, additional, Şaşmaz, Hatice İlgen, additional, Aksoy, Basak, additional, Yılmaz, Ebru, additional, Okur, Fatma, additional, Tekkeşin, Funda, additional, Yenigürbüz, Fatma Demir, additional, Ozek, Gülcihan, additional, Atay, Avni, additional, Bozkaya, İkbal Ok, additional, Çelen, Suna, additional, Ozturkmen, Seda, additional, Gunes, Adalet, additional, Gursel, Orhan, additional, Guler, Elif, additional, Özcan, Alper, additional, Uçkan, Duygu, additional, Aydogdu, Selime, additional, Özbek, Namık Yaşar, additional, Karasu, Gulsun, additional, Sezgin, Gulay, additional, Dogru, Omer, additional, Albayrak, Davut, additional, Öztürk, Gülyüz, additional, Aksoylar, Serap, additional, Daloglu, Hayriye, additional, Al, Işık Odaman, additional, Evim, Melike Sezgin, additional, Akbayram, Sinan, additional, Öncül, Yurday, additional, Zengin, Emine, additional, Albayrak, Canan, additional, Cetin, Timur, additional, Kar, Yeter Düzenli, additional, Çakmaklı, Hasan Fatih, additional, Tüfekçi, Özlem, additional, Toret, Ersin, additional, and Antmen, Bulent, additional

Published
2023
Full Text
View/download PDF

11. Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkinʼs lymphoma

Author

Hazar, Volkan, Kesik, Vural, Aksoylar, Serap, Karakukcu, Musa, Ozturk, Gulyuz, Kupesiz, Alphan, Atas, Erman, Oniz, Haldun, Kansoy, Savas, Unal, Ekrem, Tanyeli, Atila, Erbey, Fatih, Elli, Murat, Tacyildiz, Nurdan, Karasu, Gulsun Tezcan, Kocak, Ulker, Anak, Sema, Bengoa, Sebnem Yilmaz, Sezgin, Gulay, Atay, Didem, Unal, Emel, Uygun, Vedat, Kurucu, Nilgun, Kaya, Zuhre, and Yesilipek, Akif

Published
2015
Full Text
View/download PDF

15. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi

Author

YAMAN, Yöntem, ELLİ, Murat, ÖZDİLLİ, Kürşat, TELHAN, Leyla, BAYRAM, Nihan, HAZAR, Volkan, TUĞRUL, Ebru, ŞAHİN, Şifa, and ANAK, Sema

Subjects
Hodgkin Lenfoma,Kök Hücre Nakli,brentuksimab,vedotin,yüksek doz kemoterapi,kontrol noktası inhibitörü, Pediatri, Pediatrics, hodgkin lymphoma,stem cell transplantation,brentixumab,vedotin,relapse
Abstract

Background: Nearly 20% of patients with Hodgkin Lymphoma (HL) who receive standard treatment will relapse or have a refractory disease. Standard treatment for the Relapsed/Refractory (RR) HL is salvage high dose chemotherapy followed by autologous stem cell transplantation (AuSCT). Management of RR HL after AuSCT with allogeneic stem cell transplantation (ASCT) is also considered as an important salvage therapy. Objective: To describe the outcome in pediatric patients with RR HL who underwent AuHSCT and ASCT in Medipol University hematopoietic stem cell transplantation center. Method: We retrospectively evaluated 18 pediatric patients with RR HL who underwent AHSCT between November 2014 and July 2019. The evaluation of ASCT after RR HL AuSCT is also done. Results: Sixteen patients are still alive. Eleven of them relapsed after AuHSCT. AllogeneicHSCT was performed on 10 patients who relapsed. Relapse was seen in three patients after AHSCT. Eight of them are still alive., Giriş: Standart tedavi alan Hodgkin Lymphoma (HL) hastalarının yaklaşık %20’sinde hastalık dirençli seyredebilir veya tekrar edebilir. Tekrar eden/ dirençli HL’da standart tedavi yüksek doz kemoterapi ve takip eden otolog kök hücre naklidir (OKHN). Otolog KHN sonrası tekrar eden hastalarda ise allojeneik kök hücre nakli (AKHN) önemli bir kurtarma tedavisi olarak görülmektedir. Amaç: Medipol Üniversitesi Tıp Fakültesi çocuk kemik iliği nakil ünitesinde OKHN ve AKHN yapılan hastalarda sonuçları değerlendirmek. Yöntem: Tekrar eden/dirençli HL nedeniyle 2014 Kasım ile Temmuz 2019 tarihleri arasında merkezimizde OKHN yapılan 18 olgu retrospektif olarak değerlendirilmiştir. Otolog KHN sonrası hastalığı tekrar eden ve AKHN yapılan hastalarda ayrıca değerlendirilmiştir. Bulgular: Onaltı hasta halen hayattadır. Onbir hastada OKHN sonrası hastalık tekrar etmiştir. Relaps eden hastalardan 10’una AKHN yapılmıştır. Bu hastalardan üçünde tekrar görülmüş olup, sekizi nakil sonrası hayattadırlar.

Published
2020

16. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Author

Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, Pillon, Marta, Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, and Pillon, Marta

Abstract

Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.

Published
2021

17. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Author

Burkhardt, Birgit, primary, Taj, Mary, additional, Garnier, Nathalie, additional, Minard-Colin, Veronique, additional, Hazar, Volkan, additional, Mellgren, Karin, additional, Osumi, Tomoo, additional, Fedorova, Alina, additional, Myakova, Natalia, additional, Verdu-Amoros, Jaime, additional, Andres, Mara, additional, Kabickova, Edita, additional, Attarbaschi, Andishe, additional, Chiang, Alan Kwok Shing, additional, Bubanska, Eva, additional, Donska, Svetlana, additional, Hjalgrim, Lisa Lyngsie, additional, Wachowiak, Jacek, additional, Pieczonka, Anna, additional, Uyttebroeck, Anne, additional, Lazic, Jelena, additional, Loeffen, Jan, additional, Buechner, Jochen, additional, Niggli, Felix, additional, Csoka, Monika, additional, Krivan, Gergely, additional, Palma, Julia, additional, Burke, G. A. Amos, additional, Beishuizen, Auke, additional, Koeppen, Kristin, additional, Mueller, Stephanie, additional, Herbrueggen, Heidi, additional, Woessmann, Wilhelm, additional, Zimmermann, Martin, additional, Balduzzi, Adriana, additional, and Pillon, Marta, additional

Published
2021
Full Text
View/download PDF

18. Comparison of Total Body Irradiation–based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL

Author

Yalcin, Koray, primary, Pehlivan, Berrin, additional, Celen, Suna, additional, Bas, Elif Gulsah, additional, Kabakci, Canan, additional, Pashayev, Dayanat, additional, Daloglu, Hayriye, additional, Zhumatayev, Suleyman, additional, Uygun, Vedat, additional, Karasu, Gulsun Tezcan, additional, Hazar, Volkan, additional, and Yesilipek, Akif, additional

Published
2021
Full Text
View/download PDF

19. Allogeneic hematopoietic stem cell transplantation in patients with childhood cerebral adrenoleukodystrophy: A single‐center experience “Better prognosis in earlier stage”

Author

Yalcin, Koray, primary, Çelen, Suna S., additional, Daloglu, Hayriye, additional, Demir, Mustafa Kemal, additional, Öztürkmen, Seda, additional, Pasayev, Dayanat, additional, Zhumatayev, Suleimen, additional, Uygun, Vedat, additional, Hazar, Volkan, additional, Karasu, Gulsun, additional, and Yesilipek, Akif, additional

Published
2021
Full Text
View/download PDF

20. Timing of Initiation of Calcineurin Inhibitors in Pediatric Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Effects on Survival, Relapse, and Cytokine Release Syndrome.

Author

Uygun, Vedat, Karasu, Gülsün, Yalçın, Koray, Öztürkmen, Seda, Daloğlu, Hayriye, Çelen, Safiye Suna, Hazar, Volkan, and Yeşilipek, Akif

Subjects
CYCLOPHOSPHAMIDE, CYTOKINE release syndrome, CALCINEURIN, HEMATOPOIETIC stem cell transplantation
Abstract

Background: The use of unmanipulated haploidentical hematopoietic stem cell transplantations (haplo-HSCT) with post-transplant cyclophosphamide (PTCY) in children has emerged as an acceptable alternative to the patients without a matched donor. However, the timing of calcineurin inhibitors (CNIs) used in combination with PTCY is increasingly becoming a topic of controversy. Method: We evaluated 49 children with acute leukemia who underwent unmanipulated haplo-HSCT with PTCY according to the initiation day of CNIs (pre- or post-cyclophosphamide [CY]). Results: There were no significant differences in the overall survival analysis between the 2 groups. The cumulative incidence of relapse at 2 years was 21.2% in the pre-CY group and 38.9% in the post-CY group (p = 0.33). Cytokine release syndrome (CRS) was observed more frequently in the post-CY group (p = 0.04). The overall survival and event-free survival at 2 years in patients with and without CRS in the pre-CY group were 42.9% versus 87.5% (p = 0.04) and 38.1% versus 87.5% (p = 0.04), respectively. Conclusion: Our study shows that the argument for starting CNI administration after CY is tenuous, and the rationale for not starting CNIs before CY needs to be reconsidered. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Hematopoietic stem cell transplantation in CD40 ligand deficiency: A single‐center experience

Author

Uygun, Dilara Fatma Kocacık, primary, Uygun, Vedat, additional, Karasu, Gülsün Tezcan, additional, Daloğlu, Hayriye, additional, Öztürkmen, Seda Irmak, additional, Çelmeli, Fatih, additional, Törün, Selda Hançerli, additional, Özen, Ahmet, additional, Barış, Safa, additional, Aydıner, Elif Karakoç, additional, Yalçın, Koray, additional, Kılıç, Suar Çakı, additional, Hazar, Volkan, additional, Bingöl, Ayşen, additional, and Yeşilipek, Akif, additional

Published
2020
Full Text
View/download PDF

28. Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group

Author

Hazar, Volkan, primary, Karasu, Gülsün Tezcan, additional, Uygun, Vedat, additional, Özbek, Namık, additional, Karakükçü, Musa, additional, Öztürk, Gülyüz, additional, Daloğlu, Hayriye, additional, Kılıç, Suar Çakı, additional, Aksu, Tekin, additional, Ünal, Ekrem, additional, Koçak, Ülker, additional, Yeşilipek, Akif, additional, Akçay, Arzu, additional, Gürsel, Orhan, additional, Küpesiz, Alphan, additional, Okur, Fatma Visal, additional, İleri, Talia, additional, Kansoy, Savaş, additional, Bayram, İbrahim, additional, Karagün, Barbaros Şahin, additional, Gökçe, Müge, additional, Kaya, Zühre, additional, Ok Bozkaya, İkbal, additional, Patıroğlu, Türkan, additional, and Aksoylar, Serap, additional

Published
2020
Full Text
View/download PDF

36. Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group

Author

Aksoylar, Serap, Varan, Ali, Vergin, Canan, Hazar, Volkan, Akici, Ferhan, Dagdemir, Ayhan, Buyukavci, Mustafa, Kebudi, Rejin, Kurucu, Nilgun, Sevinir, Betul, Unal, Emel, Vural, Sema, Guler, Elif, Apak, Hilmi, Oniz, Haldun, Karadeniz, Ceyda, Canpolat, Cengiz, Anak, Sema, Ilhan, Inci, Ince, Dilek, Cecen, Emre, and Olgun, Nur

Subjects
Chemotherapy -- Usage, Neuroblastoma -- Care and treatment -- Research, Combined modality therapy -- Usage, Health
Abstract

Byline: Serap. Aksoylar, Ali. Varan, Canan. Vergin, Volkan. Hazar, Ferhan. Akici, Ayhan. Dagdemir, Mustafa. Buyukavci, Rejin. Kebudi, Nilgun. Kurucu, Betul. Sevinir, Emel. Unal, Sema. Vural, Elif. Guler, Hilmi. Apak, Haldun. [...]

Published
2017

39. Prognostic factors for survival in children who relapsed after allogeneic hematopoietic stem cell transplantation for acute leukemia.

Author

Hazar, Volkan, Tezcan Karasu, Gülsün, Öztürk, Gülyüz, Küpesiz, Alphan, Aksoylar, Serap, Özbek, Namık, Uygun, Vedat, İleri, Talia, Okur, Fatma Visal, Koçak, Ülker, Kılıç, Suar Çakı, Akçay, Arzu, Güler, Elif, Kansoy, Savaş, Karakükcü, Musa, Bayram, İbrahim, Aksu, Tekin, Yeşilipek, Akif, Karagün, Barbaros Şahin, and Yılmaz, Şebnem

Subjects
*HEMATOPOIETIC stem cell transplantation, *ACUTE leukemia, *PROGNOSIS, *OVERALL survival, *EXTRAMEDULLARY diseases, *CAUSES of death
Abstract

Background: Post‐transplant relapse has a dismal prognosis in children with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Data on risk factors, treatment options, and outcomes are limited. Procedure: In this retrospective multicenter study in which a questionnaire was sent to all pediatric transplant centers reporting relapse after allo‐HSCT for a cohort of 938 children with acute leukemia, we analyzed 255 children with relapse of acute leukemia after their first allo‐HSCT. Results: The median interval from transplantation to relapse was 180 days, and the median follow‐up from relapse to the last follow‐up was 1844 days. The 3‐year overall survival (OS) rate was 12.0%. The main cause of death was disease progression or subsequent relapse (82.6%). The majority of children received salvage treatment with curative intent without a second HSCT (67.8%), 22.0% of children underwent a second allo‐HSCT, and 10.2% received palliative therapy. Isolated extramedullary relapse (hazard ratio (HR): 0.607, P =.011) and relapse earlier than 365 days post‐transplantation (HR: 2.101, P <.001 for 0‐180 days; HR: 1.522, P =.041 for 181‐365 days) were found in multivariate analysis to be significant prognostic factors for outcome. The type of salvage therapy in chemosensitive relapse was identified as a significant prognostic factor for OS. Conclusion: A salvage approach with curative intent may be considered for patients with post‐transplant relapse, even if they relapse in the first year post‐transplantation. For sustainable remission, a second allo‐HSCT may be recommended for patients who achieve complete remission after reinduction treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Mesenchymal stem cell therapy for steroid refractory acute graft versus host disease

Author

Anak, Sema, Yaman, Yöntem, Özdilli, Kürşat, Bilgen, Hülya, Sarıbeyoğlu, Ebru Tuğrul, Hazar, Volkan, Ayman, Fatma Nur, and Elli, Murat

Subjects
Mesenchymal, Acute Graft, Stem Cell Therapy, Steroid Refractory
Abstract

Conference: 45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT) Location: Frankfurt, GERMANY Date: MAR 24-27, 2019 ... European Society for Blood and Marrow Transplantation

Published
2019

41. A Case of Gonadotropin-independent precocious puberty due to germ cell tumor in the frontal lobe

Author

Hacıhamdioğlu, Bülent, Yalçın, Koray, Çelen, Safiye Suna, Hazar, Volkan, İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Bülent Hacıhamdioğlu / 0000-0001-7070-6429, and Hacıhamdioğlu, Bülent

Subjects
endocrine system, urogenital system, reproductive and urinary physiology, hormones, hormone substitutes, and hormone antagonists
Abstract

It is known that gonadotropin-independent or peripheral precocious puberty (PPP) may develop due to tumors that secrete beta human chorionic gonadotropin (Beta-HCG) WOS:000485922404209 Q2

Published
2019

44. Relapse after allogeneic hematopoietic stem cell transplantation for acute leukemia in children: a survey by the Turkish Pediatric Bone Marrow Study Group of 255 cases

Author

Hazar, Volkan, Karasu, Gulsun Tezcan, Ozturk, Gulyuz, Kupesiz, Alphan, Kansoy, Savas, Ozbek, Namik, Uygun, Vedat, Ileri, Talia, Okur, Fatma Visal, Kocak, Ulker, Kilic, Suar Caki, Akcay, Arzu, Guler, Elif, Gozmen, Salih, Musa Karakukcu, Bayram, Ibrahim, Aksu, Tekin, Yesilipek, Akif, Karagun, Barboros Sahin, Bengoa, Sebnem Yilmaz, Ertem, Mehmet, Uckan, Duygu, Kaya, Zuhre, Fiskin, Tunc, Atay, Didem, Kupesiz, Funda Tayfun, Gursel, Orhan, Yaman, Yontem, Bozkurt, Ceyhun, Gokce, Muge, and Aksoylar, Serap

Subjects
surgical procedures, operative, Turkish Pediatric Bone Marrow Study Group, Allogeneic Hematopoietic, Acute Leukemia, Stem Cell Transplantation
Abstract

European Society for Blood and Marrow Transplantation

Published
2018

45. TPOG-NÖROBLASTOM 2009 PROTOKOLU: YÜKSEK RISK GRUBU- OTOLOG KÖK HÜCRE TRANSPLANTASYONU TEDAVI KOLU GÜNCEL ÖN SONUÇLARI

Author

TAÇYILDIZ, NURDAN, YÜKSEK, NAZMİYE, VARAN, ALİ, DAĞDEMİR, AYHAN, ÖZYÜREK, DERYA, HAZAR, VOLKAN, KANSOY, SAVAŞ, OĞUZ, AYNUR, TOKUÇ, AYŞE GÜLNUR, ÇORAPÇIOĞLU, FUNDA, ÜNAL, EMEL, AKYÜZ, CANAN, KEBUDİ, REJİN, GENÇ, BAHAR, AKICI, FERHAN, KÖKSAL, YAVUZ, ÖZDEMİR, GÜL NİHAL, ÇITAK, ELVAN ÇAĞLAR, ÖNİZ, HALDUN, OCAK, SÜHEYLA, ATAŞ, ERMAN, İNCE, DİLEK, ÇEÇEN, REFİK EMRE, OLGUN, HATİCE NUR, HEKİMCİ ÖZDEMİR, HAMİYET, BOZKURT, CEYHUN, AKSOYLAR, SERAP, EMİR, SUNA, GÜLER, ELİF, ÜNAL, EKREM, and DEMİRAĞ, BENGÜ

Published
2018

46. TPOG Nöroblastom 2009 protokolu: Yüksek risk grubu-otolog kök hücre transplantasyonu tedavi kolu güncel ön sonuçları

Author

GÜLER, ELİF, Emir, Suna, DAĞDEMİR, AYHAN, Akıcı, Ferhan, İNCE, DİLEK, ÇEÇEN, REFİK EMRE, OLGUN, HATİCE NUR, VARAN, ALİ, Demirağ, Bengü, ÜNAL, EKREM, Özyürek, Derya, KÖKSAL, YAVUZ, Özdemir, Hamiyet Hekimci, OCAK, SÜHEYLA, Öniz, Haldun, ÖZDEMİR, GÜL NİHAL, AKSOYLAR, SERAP, HAZAR, VOLKAN, Oğuz, Aynur, TOKUÇ, AYŞE GÜLNUR, Çorapçıoğlu, Funda, and KEBUDİ, REJİN

Published
2018

48. TPOG-Nöroblastom 2009 Protokolü: Yüksek Risk Grubu-Otolog Kök Hücre Transplantasyonu Tedavi Kolu Güncel ön Sonuçları

Author

BOZKURT, CEYHUN, VARAN, ALİ, DEMİRAĞ, BENGÜ, ÜNAL, EKREM, HEKİMCİ ÖZDEMİR, HAMİYET, TAÇYILDIZ, NURDAN, YÜKSEK, NAZMİYE, ATAŞ, ERMAN, OCAK, SÜHEYLA, ÖNİZ, HALDUN, ÇITAK, ELVAN ÇAĞLAR, ÖZDEMİR, NİHAL GÜL, GÜLER, ELİF, KÖKSAL, YAVUZ, AKICI, FERHAN, GENÇ, DİLDAR BAHAR, KEBUDİ, REJİN, AKYÜZ, CANAN, ÜNAL, EMEL, ÇORAPÇIOĞLU, FUNDA, TOKUÇ, AYŞE GÜLNUR, OĞUZ, Aynur, KANSOY, SAVAŞ, HAZAR, VOLKAN, ÖZYÜREK, DERYA, DAĞDEMİR, AYHAN, AKSOYLAR, SERAP, emir, suna, İNCE, DİLEK, ÇEÇEN, REFİK EMRE, OLGUN, HATİCE NUR, and DOĞAN, MUSTAFA

Published
2018

49. TPOG-NBL 2009 Protokolü, Yüksek Risk Grubu Otolog Kök Hücre Transplantasyonu Kolu güncel sonuçları

Author

ÜNAL, EKREM, ÇEÇEN, REFİK EMRE, OLGUN, HATİCE NUR, İNCE, DİLEK, OCAK, SÜHEYLA, Öniz, Haldun, ÖZDEMİR, GÜL NİHAL, HEKİMCİ ÖZDEMİR, HAMİYET, KÖKSAL, YAVUZ, Akıcı, Ferhan, KEBUDİ, REJİN, ÇORAPCIOĞLU, FUNDA VESİLE, TOKUÇ, AYŞE GÜLNUR, Oğuz, Aynur, HAZAR, VOLKAN, Ozyürek, derya, DAĞDEMİR, AYHAN, VARAN, ALİ, DEMİRAĞ, Bengü, GÜLER, ELİF, Emir, suna, and AKSOYLAR, SERAP

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results